Eli Lilly Says Its Antibody Therapy May Reduce Covid Hospitalisations.

Eli Lilly Says Its Antibody Therapy May Reduce Covid Hospitalisations

A 2,800 milligram dose version of the drug reduced the viral load, though the 700 mg and 7,000 mg doses.

Eli Lilly and Co.'s experimental antibody treatment for Covid-19 reduced the rate at which symptomatic patients were hospitalized compared to a placebo, according to preliminary study results released by the company and its partner.

Indianapolis-based Lilly and AbCellera Biologics Inc., a closely held Canadian biotechnology company, are co-developing neutralizing antibodies derived from one of the earliest patients in the U.S. to contract Covid-19. They are among a handful of companies, including Regeneron Pharmaceuticals Inc., AstraZeneca Plc., GlaxoSmithKline Plc and its partner Vir Biotechnology Inc. pursuing antibody therapies to combat the pandemic.

Interim results from a mid-stage trial that evaluated multiple dosages found that Lilly and AbCellera's treatment, known as LY-Cov555, was associated with a 1.7% rate in hospitalizations and ER visits among those who took the treatment compared with a 6% rate among people on a placebo, a 72% reduction in risk. No patients in the study progressed to mechanical ventilation or died.

Lilly's shares rose 0.9% to $151.48 at 10:29 a.m. in New York trading on Wednesday. The lack of a response at the highest dose and scant detail on the lower hospitalization rates drew Wall Street analyst scrutiny.

The results were "odd" Bloomberg Intelligence's Sam Fazeli wrote in a note, adding "It's not clear which dose drove the 72% reduction in hospitalizations. Very few patients were hospitalized, raising a risk that the effect is by chance. We need to see more data."

The early results also showed that one of three doses of the antibody drug tested against Covid-19 lowered the amount of virus present 11 days after patients received the treatment compared to the placebo. A 2,800 milligram dose version of the drug reduced the viral load, though the 700 mg and 7,000 mg doses did not achieve that end point. Most patients, including those receiving the placebo, demonstrated near complete viral clearance by the eleventh day.

Lilly said it will soon publish the results of this interim analysis in a peer-reviewed journal and discuss appropriate next steps with regulators.

Regeneron is expected to report results of its own at the end of this month. Jefferies analyst Biren Amin was confident the biotech company's antibody cocktail approach could prove more effective than Lilly's, which relies on a single antibody..

Warp Speed

On Tuesday, top officials at Operation Warp Speed, the Trump administration's effort to expedite the development of an inoculation and treatment, identified antibody therapies as one of its foremost R&D priorities to counter Covid.

Moncef Slaoui, who is leading the Trump Administration's Warp Speed initiative, wrote in The New England Journal of Medicine that the U.S. government plans to support manufacturing of the "most potent" monoclonal antibody products "so that hundreds of thousands of doses could be deployed this fall and winter."

Slaoui touted the potential for monoclonal antibodies not just to serve as treatments for sick patients who've become infected, but as a preventive drug for those at high-risk.

In August, Lilly and AbCellera kick-started a trial of its antibody drug in nursing homes, suggesting it may have the potential protect vulnerable groups that vaccines may not cover. Slaoui said it will continued to be tested in nursing homes, as well as "meat-packing plants, and other settings" beginning in October.

The "true utility" of neutralizing antibody treatments will be in the preventing infections in unexposed people -- not as a treatment of the virus, as seen in Wednesday's results, Evercore ISI analyst Umer Raffat said in an email.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)


Related news

Trump's Supreme Court Move «Exercise In Raw Political Power» : Joe Biden.

US presidential hopeful Joe Biden urged Senate lawmakers on Sunday to not vote on filling the Supreme Court vacancy left by Ruth Bader Ginsburg's death until after the election in November.

Democrats raise $91M after death of Ruth Bader Ginsburg.

The online fundraising organization ActBlue said grassroots donors gave US$91.4 million to Democratic candidates and causes in the 28 hours after 8 p.m. Friday, around the time the news of Ginsburg's death broke.

1 1

Judge Halts WeChat Download Ban In US-China Tech Battle.

A US judge on Sunday blocked the government's ban on WeChat downloads, hours before it was due to take effect in an ongoing technology and espionage battle between Washington and Beijing.

‘Wonderful’: Ruth Bader Ginsburg’s final summer was spent with family, friends and the opera.

Ginsburg announced in mid-July that she was receiving chemotherapy treatments, the fifth time she had dealt with cancer since 1999.

Amal Clooney Quits UK Envoy Post Over Brexit Bill

Prominent human rights lawyer Amal Clooney on Friday resigned her post as a UK envoy for media freedom, in protest at the government's "lamentable" decision to breach its EU divorce treaty.

Singh says NDP focused on getting ‘help for Canadians,’ not forcing an election.

In an interview with The West Block’s Mercedes Stephenson, Singh said he has laid out his concerns and demands for the new Parliamentary session during a meeting with Prime Minister Justin Trudeau.

1 2

Daniel Prude death: New York AG promises to expedite release of police body cam footage.

Speaking in Rochester, which has been in turmoil since the footage of Daniel Prude's fatal encounter with police was released more than five months after his death, James said her office "will be proactively releasing footage to the public on our ...

Russian jets bomb rebel-held Syria in heaviest strikes since ceasefire six months ago.

Witnesses said the warplanes struck the western outskirts of Idlib city and that there was heavy artillery shelling in the mountainous Jabal al Zawya region in southern Idlib from nearby Syrian army outposts.

Government airstrikes kill 24 civilians in northern Afghanistan, witnesses say.

The Afghan Defence Ministry, however, said the airstrikes killed 30 Taliban fighters, but added an investigation was being made into claims that civilians were among those killed.

Goal of Trump book ‘Rage’ to portray ‘the best obtainable version of truth’: Woodward.

``I hope you're recording this, so you get it down,'' Bob Woodward says, nary a hint of irony in his voice.

By continuing to browse World News (UAZMI), you acknowledge that you have read the Terms of Use and agree to the use of cookies